“…↑ MEG8: ↑ EMT process [ 9 ] | Pancreatic cancer | miR-34a and miR-203, EZH2, SNAI1 and SNAI2 | Panc1 | MEG8 was involved in EZH2 recruitment to inhibit miR-34a and miR-203 expression. ↑ MEG8: ↑ EMT process |
Hemangioma | miR203, Notch signaling pathway | HemECs | ∆ MEG8: ↓ proliferation, ↓ migration, ↑ apoptosis | [ 10 ] |
miR-497-5p, NOTCH2 | HemECs | ∆ MEG8: ↓ proliferation, ↑ ferroptosis | [ 21 ] |
Hepatocellular carcinoma | miR-367-3p, 14-3-3ζ, TGFβR1, TGFβ signaling | Human LO2 hepatocytes and HepG2, Huh7, HCCLM3, and HMCC-97 H HCC | ∆ MEG8: ↓ proliferation, ↓ migration, ↓ invasion | [ 11 ] |
Bone-invasive pituitary adenomas | miR-454-3p, TNF-α | 293T and RAW264.7 | ↑ MEG8: ↑ promoting RAW264.7 cells to destroy bone | [ 12 ] |
Wilms’ tumor | miR-23a-3p, CRK | WT cells | ∆ MEG8: ↓ viability, ↓ migration, ↓ invasion | [ 13 ] |
Diabetic nephropathy | miR-770-5p | CIHP-1 | ↑ MEG8: ↑ glucose-mediated apoptosis, ↑ miR-770-5p expression by reducing the methylation of miR-770-5p | [ 14 ] |
Atherosclerosis | miR-181a, PPARα | VSMCs | ↑ MEG8: ↓ VSMC proliferation, ↓ migration, ↑ apoptosis | [ 15 ] |
Ischemic stroke | miR-130a-5p, VEGFA | OGD-treated BMECs | ∆ MEG8: ↓ viability, ↓ migration, ↓ angio... |
…”